Key Metrics
Factor Lens
Seasonal Performance
Dividends
Per-share amounts adjusted for stock splits.
Last 12 Payouts
| Period | Ex-Date | Amount / Share |
|---|---|---|
| Q2 2026 | ~2026-06-30 | $0.1200 |
| Q2 2026 | ~2026-05-04 | $0.1200 |
| Q1 2026 | ~2026-03-31 | $0.1200 |
| Q1 2025 | ~2025-12-31 | $0.1200 |
| Q3 2025 | ~2025-09-30 | $0.1200 |
| Q2 2025 | ~2025-06-30 | $0.1200 |
| Q1 2025 | ~2025-03-31 | $0.1200 |
| Q4 2024 | ~2024-12-30 | $0.1200 |
| Q3 2024 | ~2024-09-30 | $0.1200 |
| Q2 2024 | ~2024-06-30 | $0.1200 |
| Q1 2024 | ~2024-03-31 | $0.1200 |
| Q3 2023 | ~2023-09-30 | $0.1200 |
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Viatris Inc. is a global pharmaceutical company formed through the combination of Mylan N.V. with Pfizer's Upjohn business in November 2020. The company develops, manufactures,… and distributes a diverse portfolio of branded medicines and generic drugs across four reportable segments: Developed Markets, Emerging Markets, Japan, Australia and New Zealand (JANZ), and Greater China. In 2025, Viatris sold more than 70 billion doses of medicine across more than 165 countries and territories. The company's approach bridges the traditional divide between generics and brands, combining the strengths of both to address healthcare needs globally. The company's business includes established brands such as Lipitor, Norvasc, Lyrica, EpiPen, Viagra, Creon, and Celebrex, as well as a significant generics portfolio. Viatris also maintains an innovative pipeline with late-stage and in-market growth assets sourced both internally and externally. The company operates manufacturing and distribution facilities worldwide and serves retail and pharmacy establishments, wholesalers, governments, institutions, and physicians. In 2025, Viatris delivered total revenues of $14.3 billion, returned over $1 billion to shareholders through dividends and share repurchases, and completed 60 regional transactions including the acquisition of Aculys Pharma in Japan.
- Name
- Viatris Inc.
- Industry
- Drug Manufacturers - General
- CEO
- Scott A. Smith · Chief Executive Officer
- Employees
- 40,300 as of 2025-12-31
- IPO Date
- 2019-10-25
- Phone
- (724) 514-1465
- Address
- 1000 Mylan Blvd., Canonsburg, PA 15317
- Website
- http://www.viatris.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Leo Groothuis | General Counsel (HAL Holding N.V., 2022-present) | — |
| Elisha Finney | Executive Vice President and Chief Financial Officer (1999-2017, Varian Medical Systems) | — |
| JoEllen Lyons Dillon | Executive Vice President, Strategic Developments and Capital Markets (2014-2017) | — |
| Frank D'Amelio | Executive Vice President and Chief Financial Officer (Pfizer, 2020-2022) | — |
| Scott A. Smith | Chief Executive Officer | — |
Latest News
- 2026-04-13
- 2026-04-10
- 2026-03-25
- 2026-03-23
- 2026-03-19
- 2026-03-17
- 2026-03-12
- 2026-03-04